Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA4 | P22748 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23827563 | 1.00 | KDM4E (0.37) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL30111027 | 1.00 | KDM4E (0.37) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL572568 | 0.86 | KDM4E (0.38) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL7817864 | 0.86 | KDM4E (0.38) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Water SCHEMBL7151392 | 0.85 | KDM4E (0.37) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL15542301 | 0.84 | SLC6A1 (0.36) | KMT2ACYP2D6HTR6CA1CA2 | |
| SCHEMBL3272707 | 0.84 | SLC6A1 (0.36) | KMT2ACYP2D6HTR6CA1CA2 | |
| SCHEMBL4383814 | 0.84 | SLC6A1 (0.36) | KMT2ACYP2D6HTR6CA1CA2 | |
| SCHEMBL7349678 | 0.83 | ATM (0.36) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL17276241 | 0.81 | SLC6A1 (0.31) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108480890-A | One kind being used for underground engineering waste pipe welder and its working method | 徐州工程学院 | 2018-09-04 | — | — | CN | claimed |
| CN-1976904-A | Pyridazin-3 (2H) -one derivatives and their use as PDE4 inhibitors | ALMIRALL LAB (ES) | 2007-06-06 | — | — | CN | claimed |
| CN-114213415-A | Macrocyclic pyrimidine derivatives | 詹森药业有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-106164075-B | Macrocyclic pyrimidine derivatives | 詹森药业有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | ERASCA, INC. | 2021-09-23 | — | — | US | disclosed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | disclosed |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| EP-3126364-B1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-07 | — | — | EP | disclosed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | disclosed |
| EP-3126364-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022202-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| CN-106164075-A | Macrocyclic pyrimidine derivatives | 詹森药业有限公司 | 2016-11-23 | — | — | CN | disclosed |
| WO-2015150555-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
| EP-2168958-A1 | Isoindole-Imide Compounds, Compositions And Uses Thereof | CELGENE CORPORATION (US) | 2010-03-31 | — | — | EP | disclosed |
| CN-1976904-A | Pyridazin-3 (2H) -one derivatives and their use as PDE4 inhibitors | ALMIRALL LAB (ES) | 2007-06-06 | — | — | CN | disclosed |
| EP-1767533-A1 | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor | CELGENE CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022202-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | EEF2K, VPS26B, VPS28 | KDM4E 1710/4885MAPT 3442/4885KMT2A 3569/4885 |
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | SDHB, CCNI, SDHA | KDM4E 2603/4885MAPT 2372/4885KMT2A 2767/4885 |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | EEF2K, VPS26B, VPS28 | KDM4E 1710/4885MAPT 3442/4885KMT2A 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.